Klomberg Renz C W, Vlug Lotte E, de Koning Barbara A E, de Ridder Lissy
Division of Gastroenterology, Department of Pediatrics, Erasmus MC Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, Netherlands.
Front Pediatr. 2022 Apr 28;10:885876. doi: 10.3389/fped.2022.885876. eCollection 2022.
In children with gastrointestinal disorders such as inflammatory bowel disease (IBD) and intestinal failure (IF), the risk of venous thromboembolism (VTE) is increased. VTE may lead to pulmonary embolism, sepsis and central line infection, stroke and post-thrombotic syndrome. The purpose of this review is to summarize current knowledge and recent advances around VTE management in pediatric gastroenterology with a focus on IBD and IF. The VTE incidence in children with IBD is reported to be around 4-30 per 10,000 patient-years, with higher incidences for hospitalized children. While in general, IF is less common than IBD, the VTE incidence in children with IF is around 750 per 10,000 patient-years. The most common risk factors for development of VTE involve deviations leading to Virchow's triad (endothelial damage, stasis, and hypercoagulability) and include active inflammation, particularly with colonic involvement, presence of a central venous catheter, underlying thrombophilia, reduced mobility, surgery, and hospitalization. Classes of anticoagulants used for treatment of VTE are low molecular weight heparins and vitamin K antagonists. However, the use of direct oral anticoagulants for treatment or prevention of VTE has not been studied in this pediatric population yet. Pediatric gastroenterologists apply different VTE prevention and treatment strategies due to lack of literature and lack of consensus. We discuss the role of primary and secondary prophylactic use of anticoagulants, and provide tools and recommendations for screening, prevention and management for the specific pediatric populations.
在患有炎症性肠病(IBD)和肠衰竭(IF)等胃肠道疾病的儿童中,静脉血栓栓塞(VTE)的风险会增加。VTE可能导致肺栓塞、败血症和中心静脉导管感染、中风以及血栓形成后综合征。本综述的目的是总结小儿胃肠病学中VTE管理的当前知识和最新进展,重点关注IBD和IF。据报道,IBD患儿的VTE发病率约为每10000患者年4 - 30例,住院患儿的发病率更高。虽然一般来说,IF比IBD少见,但IF患儿的VTE发病率约为每10000患者年750例。VTE发生的最常见风险因素涉及导致维勒布兰德三联征(内皮损伤、血流淤滞和高凝状态)的偏差,包括活动性炎症,尤其是累及结肠时、中心静脉导管的存在、潜在的血栓形成倾向、活动减少、手术和住院。用于治疗VTE的抗凝剂类别为低分子量肝素和维生素K拮抗剂。然而,在这一儿科人群中,直接口服抗凝剂用于治疗或预防VTE的情况尚未得到研究。由于缺乏文献和共识,小儿胃肠病学家采用不同的VTE预防和治疗策略。我们讨论了抗凝剂一级和二级预防性使用的作用,并为特定儿科人群的筛查、预防和管理提供工具和建议